Clovis Oncology's rucaparib ARIEL3 study data published in The Lancet
Clovis Oncology announced that comprehensive data from the Phase 3 ARIEL3 study of rucaparib for maintenance treatment of advanced ovarian cancer were published online in The Lancet. The ARIEL3 study successfully achieved its primary and key secondary endpoints. September 13, 2017